International Clinical Trial: A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07462468) titled 'A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer' on March 4.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: WestVac Biopharma Co., Ltd.

Condition: Platinum-resistant Recurrent Ovarian Cancer (PROC)

Intervention: Drug: WSK-IM02

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 10, 2026

Target Sample Size: 36

To know more, visit https://clinicaltrials....